Possible Interaction: 3-Nitrotyrosine and Rosiglitazone

“ Rosiglitazone significantly reduced plasma nitrotyrosine , high-sensitivity C-reactive protein, and von Willebrand antigen (P < .03 for all) and significantly increased plasma adiponectin (P < .05).”

“Immunohistochemical reactions against ICAM-1 and nitrotyrosine showed that rosiglitazone decreased the intensity of inflammatory reactions in the groups of treated animals.”

“Administration of rosiglitazone and 15d-PGJ2 also markedly reduced the nitrotyrosine , PARP and inducible nitric oxide synthase formation.”

“Immunohistochemical analysis revealed that rosiglitazone inhibited the formation of nitrotyrosine , a marker for peroxynitrite reactivity, in the lung tissue.”

“Furthermore, rosiglitazone reduced: (1) the increase in the staining (immunohistochemistry) for nitrotyrosine and poly (ADP-ribose) polymerase (PARP), (2) the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), intercellular adhesion molecules-1 (ICAM-1) and P-selectin in the lungs of carrageenan-treated rats.”

“Treatment with rosiglitazone enhanced PPAR&ggr; expression, improved endothelium-dependent vasodilatation, preserved P-VASP, suppressed gp91phox and iNOS expression, reduced superoxide and total NOx production, and inhibited nitrotyrosine formation.”

“Administration of rosiglitazone and 15d-PGJ2 also markedly reduced the nitrotyrosine formation and the upregulation of ICAM-1 during reperfusion.”